Better Context → Better Decisions
Context counts in life sciences. The FENIX analyst team is tirelessly using its experience to put you in a position to succeed. Below, our readers without corporate access will find a wealth of contextualized life science insight ready to be purchased in the FENIX Marketplace. If our content sharing limitations are inconvenient for you, reach out to Brady for unlimited corporate, institutional, or individual access.
$599
Posted in: Bolus Insulin, Dual/triple agonist, GLP-1RA, Glucose Monitoring, Insulin Delivery, SGLT2i Dec 19 | 2018Lilly 2019 Guidance SummaryPurchase Blast$599
Posted in: Basal Insulin, Insulin Delivery Dec 19 | 2018Gan and Lee + Sandoz and FDA Biosimilar Insulin BLA ListPurchase Blast$599
Posted in: Glucose Monitoring, Insulin Delivery, Other Dec 14 | 2018Lilly's Evidation Health Collaboration Expanded To Discover Novel Digital Health MeasuresPurchase Blast$599
Posted in: Glucose Monitoring, Insulin Delivery Dec 13 | 2018Tidepool Loop funded at $6MPurchase Blast$599
Posted in: GLP-1RA, Glucose Monitoring Dec 12 | 2018New Sanofi and Dexcom trials: Efpeglenatide add-on to MET+/-SU and G6 vs. Libre FGMPurchase Blast$599
Posted in: Glucose Monitoring Dec 06 | 2018CGM: Novel Non-invasive Platform Similar To Libre CGM DataPurchase Blast$599
Posted in: Other Dec 05 | 2018Sanofi cuts ~670 jobs and adds 250 employees in FrancePurchase Blast$599
Posted in: Bolus Insulin, Insulin Delivery Dec 04 | 2018New Mylan and Lilly trials: Ph3 biosimilar insulin aspart study, Ph2 URLi study in 670GPurchase Blast$599
Posted in: SGLT2i Nov 30 | 2018Nothing New in Sota Adcom Federal Register AnnouncementPurchase Blast$599
Posted in: SGLT2i Nov 29 | 2018Sotagliflozin Adcom in T1DM Scheduled for January 17, 2019Purchase Blast$599
Posted in: Basal Insulin Nov 28 | 2018New Novo Ph2 study for QW Insulin 287 in T2DMPurchase BlastGet the Latest Analysis
Stay informed and aligned with frequent updates to keep a pulse on the industry.
If you already have an account, please log in. If you have any questions or would like to subscribe to our services, please contact Brady.
